RxDoctor Payments Data

David Loewy, MD

Ophthalmology · Winter Haven, FLNPI 1679575831

Payments from drug & device makers

$772in general payments, 2019–2025

Across 10 payments — averaging $77.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$372
  • Coopervision Inc.$107
  • Johnson & Johnson Vision Care, Inc.$105
  • Alcon$101
  • Regeneron Healthcare Solutions, Inc.$58
  • Alcon Research LLC$29

What the payments were for

  • Food & beverage$772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$772 in reported general payments places this provider in the 30th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$391,261
Medicare patients
726
Services billed
3,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost96$47,446
RocklatanNetarsudil Mesylat/Latanoprost38$29,816
RestasisCyclosporine20$21,862
Alphagan PBrimonidine Tartrate40$16,708
XiidraLifitegrast14$12,618
RhopressaNetarsudil Mesylate24$11,483
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol54$8,739
Cyclosporine15$8,736
Prednisolone Acetate163$7,773
Travoprost52$7,509
CombiganBrimonidine Tartrate/Timolol17$7,443
Latanoprost540$7,325
SimbrinzaBrinzolamide/Brimonidine Tart20$5,834
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat201$3,045
Brimonidine Tartrate199$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$372$12,61814 claims
AlconSimbrinza$101$5,83420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →